510(k) Premarket Notification: Liberty Glucose Normal Control Solution American Biological Technologies, Inc.

# MAR 9 2006

# 5. 510(k) Summary

# Introduction:

According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.

# Submitter:

Liberty Healthcare Group, Inc. 8883 Liberty Lane Port St. Luce, FL 34952

# Contact Person:

John C. Gormley   
American Biological Technologies, Inc.   
940 Crossroads Blvd   
Seguin, TX 78155   
(830) 372-1391 ex. 210   
Establishment Registration Number: 1643621

# Device Name:

Liberty Glucose Normal Control Solution

Common Name:

Single Analyte Control Solution, All Types (Assayed and Unassayed)

# Classification Name:

Quality Control Material (assayed and unassayed).

Classification:

Class I per 21 CFR 862.1660

Product Code:

75 JJX

Panel:

Chemistry

Predicate Devices:

Name:

Bayer Ascensia AuToDisc Normal Control   
Bayer Healthcare, LLC.   
K963500

Manufacturer: 510(k) No.:

Name: Manufacturer: 510(k) No.:

Liberty Glucose Control Liberty Healthcare Group K052980

510(k) Premarket Notification: Liberty Glucose Normal Control Solution American Biological Technologies, Inc.

# Device Description:

The Liberty Glucose Normal Control Solution consists of a viscosity-adjusted, aqueous liquid control solution containing a known quantity of glucose. The product is packaged in plastic dropper tipped bottles for easy application of the control solutions to the test strips and a red coloration to aid the user to visually confirm application of the control. The product is nonhazardous and contains no human or animal derived materials.

# Intended Use:

The Liberty Glucose Normal Control Solution is intended for in vitro diagnostic use (i.e. for external use only) by healthcare professionals and in the home by people with diabetes mellitus to assess the performance of Bayer Ascensia DEX 2/DEX and BREEZE Blood Glucose Monitors.

# Comparison to Predicate Device:

<table><tr><td rowspan=1 colspan=1>Aspect</td><td rowspan=1 colspan=1>licate levice:</td><td rowspan=1 colspan=1>Icaterevce.</td><td rowspan=1 colspan=1>7New.Product.</td></tr><tr><td rowspan=1 colspan=1>Name</td><td rowspan=1 colspan=1>Ascensia Autodisc NormalControl</td><td rowspan=1 colspan=1>Liberty Glucose Control</td><td rowspan=1 colspan=1>Liberty GlucoseNormal ControlSolution</td></tr><tr><td rowspan=1 colspan=1>510(k), Date</td><td rowspan=1 colspan=1>K963500, 01/21/1997</td><td rowspan=1 colspan=1>K052980 11/30/2005</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Number ofLevels</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>Glucose</td><td rowspan=1 colspan=1>Glucose</td><td rowspan=1 colspan=1>Glucose</td></tr><tr><td rowspan=1 colspan=1>Container</td><td rowspan=1 colspan=1>Plastic bottle with dropper-tip</td><td rowspan=1 colspan=1>Plastic bottle withdropper-tip</td><td rowspan=1 colspan=1>Plastic bottle withdropper-tip</td></tr><tr><td rowspan=1 colspan=1>Fill Volume</td><td rowspan=1 colspan=1>2.5 mL</td><td rowspan=1 colspan=1>3.6 mL</td><td rowspan=1 colspan=1>3.6 mL</td></tr><tr><td rowspan=1 colspan=1>Color</td><td rowspan=1 colspan=1>Red</td><td rowspan=1 colspan=1>Red</td><td rowspan=1 colspan=1>Red</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Red solutions containing ameasured amount ofglucose.</td><td rowspan=1 colspan=1>Buffered aqueoussolution of D-Glucose,viscosity modifiers,preservatives, and othernon-reactive ingredients</td><td rowspan=1 colspan=1>Buffered aqueoussolution of D-Glucose,viscosity modifiers,preservatives, andother non-reactiveingredients</td></tr><tr><td rowspan=1 colspan=1>Indications forUse</td><td rowspan=1 colspan=1>For use with an appropriateAscensia/Glucometer BloodGlucose Meter andAscensia AuTODisc TestStrip Disc as a qualitycontrol check to verify theaccuracy of blood glucosetest results.</td><td rowspan=1 colspan=1>Used to check theperformance ofMedisense BloodGlucose Systems only.</td><td rowspan=1 colspan=1>To check theperformance of theBayer Ascensia DEX2/DEX and BREEZEBlood GlucoseMonitors.</td></tr><tr><td rowspan=1 colspan=1>TargetPopulation</td><td rowspan=1 colspan=1>Professional and home use</td><td rowspan=1 colspan=1>Professional and homeuse</td><td rowspan=1 colspan=1>Professional andhome use</td></tr></table>

510(k) Premarket Notification: Liberty Glucose Normal Control Solution American Biological Technologies, Inc.

# Performance Studies:

Tests were performed to verify specific performance characteristics:

Stability (Accelerated and Real-time)   
Open Vial   
Microbial Stress Stability   
Test precision

# Conclusion:

Comparison of the performance characteristics, formulation and intended use support the claim of substantial equivalence.

# MAR 9 2006

Liberty Healthcare Group, Inc.   
c/o Mr. John Gromley   
Vice President, Quality Assurance /Regulatory Affairs American Biological Technologies, Inc.   
940 Crossroads Blvd.   
Seguin, Texas 78155

Re: k060426 Trade/Device Name: Liberty Glucose Normal Control Solution Regulation Number: 21 CFRÂ§862.1660 Regulation Name: Quality control material (assayed and unassayed) Regulatory Class: Class I Product Code: JJX Dated: February 21, 2006 Received: February 21, 2006

Dear Mr. Gromley:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class II (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2 -

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

![](images/5434701e01b632c232e7fd4f46b099fadfca5951b91e354eae85e677c32bae8f.jpg)

Alberto Gutierrez, Ph.D.   
Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device Evaluation and Safety   
Center for Devices and Radiological Health

# Indications for Use

510(k) Number (if known): K060426

Device Name: Liberty Glucose Normal Control Solution

Indications For Use:

For in vitro diagnostic use (i.e. for external use only) by healthcare professionals and in the home by people with diabetes mellitus to assess the performance of Bayer Ascensia DEX 2/DEX and BREEZE Blood Glucose Monitors.

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)